PhenoPath acquired by Quest Diagnostics
Please read the attached letter for an important announcement regarding PhenoPath
We are proud to announce that PhenoPath is now a Quest Diagnostics Company.
PhenoPath publishes a quarterly newsletter devoted to current diagnostic and prognostic cancer topics. The articles are authored by our pathology and scientific staff. Past newsletters can be accessed via the links below.
Please read the attached letter for an important announcement regarding PhenoPath
New FDA Approvals for PD-L1/PD-1 Targeted Therapies & Introducing the Combined Positive Score (CPS); New Assays MUC4 IHC and TFE3 (Xp11) FISH; Amyloid Analysis; etc.
PhenoPath newsletter featuring the latest on RAS gene testing, "double-hit" B cell lymphomas, and a new marker for small cell carcinoma of the ovary.
PD-L1 Testing Update, Plasma Based “Liquid Biopsy” Testing for EGFR Mutations, HER2 Clone 4B5, H3K27me3, PhenoPath at USCAP and NCCN, and more!
PD-L1 Update, Flow Cytometry, Kappa / Lambda ISH, Molecular Testing in Colorectal Carcinoma, Webinar, and more!
PhenoPath at USCAP, Open House Event, PD-L1 (22C3 and 28-8) and EGFR T790M testing at PhenoPath, BAP1 and P16 FISH in malignant mesothelioma, and more!
PhenoPath Cytogenetics / New IHC Markers in Hematologic Diseases and Solid Tumors / Recent Publications
Technical FISH Services Available / New Publications / New IHC Antibodies / Etc.
New Tests / Tests Under Development / Important Test Utilization and Reporting News / Etc.
Lynch Syndrome Algorithm / 1q21+1p21 in Multiple Myeloma / PhenoPath Introduces Multiplex Assays / AJSP publication / Etc.
New Tests / Tests Under Development / Important Test Utilization and Reporting News / Etc.
New Tests and Panels / Tests Under Development / Specimen Requirement Changes
View Newsletter »
PhenoPath Supports African Burkitt Lymphoma Projects / MSI Testing by PCR / FUS (16p11) translocations / Lung and Breast Flier Release / New Heme Antibodies
View Newsletter »
New Tests and Panels / Tests Under Development / Specimen Requirement Changes
View Newsletter »
2013 Updated ASCO-CAP HER2 Testing Guidelines in Breast Cancer/PhenoPath at the USCAP/Three Robust Antibodies in Classification of Low-Grade B Cell Lymphomas
View Newsletter »
Regan Fulton, MD, PhD, Joins PhenoPath / ROS1 FISH / GATA-3: a novel marker of breast and urothelial carcinomas / PhenoCases
View Newsletter »
Harvey Greisman, MD, PhD, Joins PhenoPath / AML FISH Panel / New Crop of IHC Markers Now Available / 10-Color Flow Cytometers
View Newsletter »
PhenoPath at USCAP / New Test KRAS Therascreen IVD / MDS Panel
View Newsletter »
New Web Site / Pathology Reference Guide Released / New Tests Available (IDH1, PTEN, CD42b, CD61, CD71, cobas® 4800 BRAF V600E)
View Newsletter »
Major & Minor BCR-ABL1 RNA and JAK2 V617F Testing by PCR / Other New Test Offerings
View Newsletter »
HER2 Testing Protocol / FDA-Approved ALK FISH / Other New Test Offerings
View Newsletter »
Myeloma FISH Panel / HER2 Assessment in Breast Cancer via FISH and RT-PCR / Subclassifying Lung Carcinoma / TTF-1 Expression in Breast Cancer
View Newsletter »
Kappa Light Chain PCR / Brachyury IHC / Other New Test Offerings
View Newsletter »
Validation of ER/PR IHC per ASCO-CAP Guidelines / KRAS Mutation Analysis by PCR / Other New Test Offerings
View Newsletter »
Announcing 10-Color Flow Cytometry / New ASCO-CAP Guidelines for ER/PR / CLL/SLL FISH
View Newsletter »
Subclassification of DLBCL by IHC / Anti-bcl-2 Clone C2 / 3,000 Breast Cancers Retested by PhenoPath
View Newsletter »
EGFR Mutation Analysis by PCR / Diagnosing Mesothelioma / Other New Test Offerings
View Newsletter »
Test Validation / SMS/RARA FISH / DOG1 IHC / Recent Publications
View Newsletter »
New Tests Available at PhenoPath (PAX8 and MDM2 by IHC; BRAF by PCR)
View Newsletter »
KRAS Testing for Colorectal Tumors / Landmark HER2 Testing Concordance Study Published
View Newsletter »
Carcinomas of Unknown Primary Markers / New Test Offerings / Optimal Specimen Handling for Myeloid Stem Cell Neoplasms
View Newsletter »
Carcinomas of Unknown Primary Panel Selection / Other New Test Offerings / Optimal Specimen Handling for Lymphoma and/or Plasma Cell Dyscrasia
View Newsletter »
PhenoPath at the USCAP Meeting / Best Practices Guides to Diagnostic Immunohistochemistry
View Newsletter »
t(9;22) BCR/ABL & RARA Breakapart FISH / PhenoPath's HER2 QA Program / Recent Publications
View Newsletter »
HER2 Testing Validation / Molar Pregnancies / Recent Publications
View Newsletter »
Introducing PhenoNet (PhenoPath's web-based reporting tool) / Making Urgent Diagnoses in Hematopathology / HER2 Validation Studies / New Test Offerings
View Newsletter »
ASCO-CAP HER2 Testing Guidelines / Landmark Study on Estrogen Receptor IHC Testing / HER2 Reflex Testing and Concordance Studies / CLL/SLL FISH
View Newsletter »
Intracystic Papillary Carcinomas / TOP2A FISH Studies / Tissue Fixation / B and T Cell by PCR
View Newsletter »
Direct and Indirect Clonality Testing at PhenoPath (by IHC, FISH, Flow and PCR)
View Newsletter »
Mesothelioma Study Published / Specialized Dermatopathology Services
View Newsletter »
PhenoPath at USCAP / FISH Studies for Oligodendrogliomas / Launch of Flow Cytometry Service / New Test Offerings
View Newsletter »